These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 19138011

  • 1. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [Abstract] [Full Text] [Related]

  • 2. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 7. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 8. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Jun; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 9. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.
    Cancer; 2004 Aug 01; 101(3):541-9. PubMed ID: 15274067
    [Abstract] [Full Text] [Related]

  • 10. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

  • 11. Bone loss in prostate cancer: evaluation, treatment and prevention.
    Saad F.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
    [Abstract] [Full Text] [Related]

  • 12. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK.
    Urol Nurs; 2006 Aug 01; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [Abstract] [Full Text] [Related]

  • 13. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 14. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep 01; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 15. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N, Huynh CC, Rashid P.
    Aust Fam Physician; 2006 Apr 01; 35(4):243-5. PubMed ID: 16642243
    [Abstract] [Full Text] [Related]

  • 16. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V, Reeves DJ.
    J Oncol Pharm Pract; 2012 Mar 01; 18(1):84-90. PubMed ID: 21807761
    [Abstract] [Full Text] [Related]

  • 17. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K, Machida T, Yoshida K.
    Nihon Rinsho; 2005 Apr 01; 63(4):721-6. PubMed ID: 15828242
    [Abstract] [Full Text] [Related]

  • 18. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 19. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.
    Can J Urol; 2005 Jun 01; 12 Suppl 2():9-15. PubMed ID: 16018826
    [Abstract] [Full Text] [Related]

  • 20. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 01; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.